ViiV Healthcare Announces FDA's Priority Review Designation For Cabotegravir

ViiV Healthcare announced the FDA has accepted and granted priority review for a New Drug Application for investigational cabotegravir long-acting for pre-exposure prophylaxis, or PrEP. The target approval date is 24 January 2022.

If approved, cabotegravir would be the first, long-acting therapy for the prevention of HIV for individuals at risk of sexually acquired HIV-1, who have a negative HIV-1 test prior to initiation, the company noted.

ViiV Healthcare said it will begin submissions of cabotegravir long-acting for PrEP to other regulatory authorities by the end of 2021.

ViiV Healthcare is a specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and... Shares of Nestle SA were gaining around 4 percent in Swiss trading after the food and beverage giant on Wednesday raised its fiscal 2021 organic sales growth forecast after reporting higher sales in the first nine of the year. For the full year, the company now expects organic sales growth between 6 percent and 7 percent.
Follow RTT